Keratoconus is a common progressive, bilateral (but usually asymmetric, one eye being more involved than the other) corneal condition, occurring in about 20 in 1000 people in India. The condition typically starts in adolescence and early adulthood. Usually one eye is involved more than the other. It is more common in people with allergies or those who rub their eyes frequently
The cornea is the clear regular spherical dome shaped window on the front of the eye. Normal pressure within the eye causes the cornea to bulge forward into an irregular cone shape in keratoconus.


Corneal Collagen Crosslinking with Riboflavin (abbreviated to C3R) LINK also called Crosslinking CXL is the globally accepted first line treatment for stabilization of the corneal ectasia (bulge) in keratoconus. C3R causes the collagen fibrils to thicken, stiffen, and crosslink & re-attach to each other, making the cornea stronger and more stable thus convincingly halting the progression of the disease.

This treatment is aimed at arresting the further progression of keratoconus by strengthening the corneal architecture (biomechanical strength). Biomechanical measurements have shown an impressive increase in corneal rigidity of over 300% after crosslinking. and thereby prevent further deterioration in vision and frequently averts the need for corneal transplantation later.